{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:47:06Z","timestamp":1792568826488,"version":"4.5.0"},"reference-count":317,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.pharmthera.2010.07.008","type":"journal-article","created":{"date-parts":[[2010,8,12]],"date-time":"2010-08-12T08:56:28Z","timestamp":1281603388000},"page":"305-323","source":"Crossref","is-referenced-by-count":24,"title":["The therapeutic potential of G-protein coupled receptors in Huntington's disease"],"prefix":"10.1016","volume":"128","author":[{"given":"Megan J.","family":"Dowie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Scotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.pharmthera.2010.07.008_bb0005","doi-asserted-by":"crossref","first-page":"13361","DOI":"10.1016\/S0021-9258(18)42219-3","article-title":"Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate\/Ca2+ signal transduction","volume":"267","author":"Abe","year":"1992","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.nurt.2008.01.008","article-title":"Symptomatic treatment of Huntington disease","volume":"5","author":"Adam","year":"2008","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0015","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.nbd.2004.04.001","article-title":"A cell-based screen for drugs to treat Huntington's disease","volume":"16","author":"Aiken","year":"2004","journal-title":"Neurobiol Dis"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00002826-199510000-00005","article-title":"Acute challenge with apomorphine in Huntington's disease: a double-blind study","volume":"18","author":"Albanese","year":"1995","journal-title":"Clin Neuropharmacol"},{"issue":"34","key":"10.1016\/j.pharmthera.2010.07.008_bb0025","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1523\/JNEUROSCI.23-34-10982.2003","article-title":"Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively","volume":"23","author":"Alfinito","year":"2003","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0030","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jchemneu.2009.02.001","article-title":"Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease","volume":"37","author":"Allen","year":"2009","journal-title":"J Chem Neuroanat"},{"issue":"6653","key":"10.1016\/j.pharmthera.2010.07.008_bb0035","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/39885","article-title":"Anterograde transport of brain-derived neurotrophic factor and its role in the brain","volume":"389","author":"Altar","year":"1997","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmthera.2010.07.008_bb0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0166-2236(98)01273-9","article-title":"Neurotrophin trafficking by anterograde transport","volume":"21","author":"Altar","year":"1998","journal-title":"Trends Neurosci"},{"issue":"41","key":"10.1016\/j.pharmthera.2010.07.008_bb0045","doi-asserted-by":"crossref","first-page":"34840","DOI":"10.1074\/jbc.M504508200","article-title":"Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin","volume":"280","author":"Anborgh","year":"2005","journal-title":"J Biol Chem"},{"issue":"41","key":"10.1016\/j.pharmthera.2010.07.008_bb0050","doi-asserted-by":"crossref","first-page":"34840","DOI":"10.1074\/jbc.M504508200","article-title":"Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin","volume":"280","author":"Anborgh","year":"2005","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0055","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/hmg\/ddi443","article-title":"Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1\/2 protects against mutant huntingtin-associated toxicity","volume":"15","author":"Apostol","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"10","key":"10.1016\/j.pharmthera.2010.07.008_bb0065","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1073\/pnas.2628045100","article-title":"A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila","volume":"100","author":"Apostol","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7010","key":"10.1016\/j.pharmthera.2010.07.008_bb0070","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb0075","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1399-0004.2007.00784.x","article-title":"The Huntington's disease quality of life battery for carers: reliability and validity","volume":"71","author":"Aubeeluck","year":"2007","journal-title":"Clin Genet"},{"key":"10.1016\/j.pharmthera.2010.07.008_bb0080","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1749-6632.2003.tb07541.x","article-title":"Mitochondria as a target for neurotoxins and neuroprotective agents","volume":"993","author":"Bachurin","year":"2003","journal-title":"Ann NY Acad Sci"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0085","doi-asserted-by":"crossref","DOI":"10.1042\/AN20090006","article-title":"Regulated release of BDNF by cortical oligodendrocytes is mediated through metabotropic glutamate receptors and the PLC pathway","volume":"1","author":"Bagayogo","year":"2009","journal-title":"ASN Neuro"},{"issue":"18","key":"10.1016\/j.pharmthera.2010.07.008_bb0090","doi-asserted-by":"crossref","first-page":"18840","DOI":"10.1074\/jbc.M313470200","article-title":"Hetero-oligomerization between GABAA and GABAB receptors regulates GABAB receptor trafficking","volume":"279","author":"Balasubramanian","year":"2004","journal-title":"J Biol Chem"},{"issue":"17","key":"10.1016\/j.pharmthera.2010.07.008_bb0095","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1523\/JNEUROSCI.3920-03.2004","article-title":"Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor","volume":"24","author":"Baquet","year":"2004","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.wco.0000084223.82329.bb","article-title":"Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?","volume":"16","author":"Bates","year":"2003","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0105","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nbd.2007.04.012","article-title":"Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes","volume":"27","author":"Battista","year":"2007","journal-title":"Neurobiol Dis"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0110","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1471-4159.2009.06302.x","article-title":"The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies","volume":"110","author":"Bauer","year":"2009","journal-title":"J Neurochem"},{"issue":"19","key":"10.1016\/j.pharmthera.2010.07.008_bb0115","doi-asserted-by":"crossref","first-page":"13153","DOI":"10.1074\/jbc.M809229200","article-title":"Inhibition of Rho kinases enhances the degradation of mutant huntingtin","volume":"284","author":"Bauer","year":"2009","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0120","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1471-4159.1993.tb03633.x","article-title":"Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate","volume":"61","author":"Beal","year":"1993","journal-title":"J Neurochem"},{"issue":"6066","key":"10.1016\/j.pharmthera.2010.07.008_bb0125","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/321168a0","article-title":"Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid","volume":"321","author":"Beal","year":"1986","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmthera.2010.07.008_bb0130","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1523\/JNEUROSCI.08-10-03901.1988","article-title":"Systemic approaches to modifying quinolinic acid striatal lesions in rats","volume":"8","author":"Beal","year":"1988","journal-title":"J Neurosci"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0135","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1006\/nbdi.1998.0168","article-title":"Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length","volume":"4","author":"Becher","year":"1998","journal-title":"Neurobiol Dis"},{"issue":"10","key":"10.1016\/j.pharmthera.2010.07.008_bb0140","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/hmg\/ddn033","article-title":"Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II","volume":"17","author":"Benchoua","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"Pt 6","key":"10.1016\/j.pharmthera.2010.07.008_bb0145","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1042\/BST0371270","article-title":"Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease","volume":"37","author":"Bithell","year":"2009","journal-title":"Biochem Soc Trans"},{"issue":"20","key":"10.1016\/j.pharmthera.2010.07.008_bb0150","doi-asserted-by":"crossref","first-page":"9122","DOI":"10.1523\/JNEUROSCI.22-20-09122.2002","article-title":"The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity","volume":"22","author":"Blum","year":"2002","journal-title":"J Neurosci"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0155","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1474-4422(03)00411-3","article-title":"Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics","volume":"2","author":"Blum","year":"2003","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.pharmthera.2010.07.008_bb0160","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1073\/pnas.0511256103","article-title":"Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases","volume":"103","author":"Bodner","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.07.008_bb0165","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ncb1063","article-title":"Cytochrome c binds to inositol (1, 4, 5) trisphosphate receptors, amplifying calcium-dependent apoptosis","volume":"5","author":"Boehning","year":"2003","journal-title":"Nat Cell Biol"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0170","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1345\/aph.1C352","article-title":"Mirtazapine in suicidal Huntington's disease","volume":"37","author":"Bonelli","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"21","key":"10.1016\/j.pharmthera.2010.07.008_bb0175","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington's disease: an evidence-based review","volume":"12","author":"Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb0180","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI27607","article-title":"Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase","volume":"116","author":"Borrell-Pages","year":"2006","journal-title":"J Clin Invest"},{"issue":"22","key":"10.1016\/j.pharmthera.2010.07.008_bb0185","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1007\/s00018-006-6242-0","article-title":"Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies","volume":"63","author":"Borrell-Pages","year":"2006","journal-title":"Cell Mol Life Sci"},{"issue":"18","key":"10.1016\/j.pharmthera.2010.07.008_bb0190","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.2174\/138161207780858384","article-title":"JNK signalling: a possible target to prevent neurodegeneration","volume":"13","author":"Borsello","year":"2007","journal-title":"Curr Pharm Des"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0195","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1042\/bj3120637","article-title":"Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1","volume":"312","author":"Bouaboula","year":"1995","journal-title":"Biochem J"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0200","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/glia.10243","article-title":"Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes","volume":"43","author":"Brambilla","year":"2003","journal-title":"Glia"},{"issue":"20","key":"10.1016\/j.pharmthera.2010.07.008_bb0205","doi-asserted-by":"crossref","first-page":"8911","DOI":"10.1523\/JNEUROSCI.22-20-08911.2002","article-title":"Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation","volume":"22","author":"Brami-Cherrier","year":"2002","journal-title":"J Neurosci"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0210","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/ana.410230605","article-title":"Differential cognitive impairment in Alzheimer's disease and Huntington's disease","volume":"23","author":"Brandt","year":"1988","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb0215","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.410410514","article-title":"Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia","volume":"41","author":"Browne","year":"1997","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.07.008_bb0220","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0028-3908(00)00079-4","article-title":"Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective","volume":"39","author":"Bruno","year":"2000","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0225","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1471-4159.2005.03074.x","article-title":"In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol","volume":"93","author":"Butovsky","year":"2005","journal-title":"J Neurochem"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2010.07.008_bb0230","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0006-8993(97)01566-7","article-title":"5-HT1B receptor binding in degenerative movement disorders","volume":"790","author":"Castro","year":"1998","journal-title":"Brain Res"},{"issue":"23","key":"10.1016\/j.pharmthera.2010.07.008_bb0235","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2174\/138161208785740018","article-title":"The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases","volume":"14","author":"Centonze","year":"2008","journal-title":"Curr Pharm Des"},{"issue":"1386","key":"10.1016\/j.pharmthera.2010.07.008_bb0240","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1098\/rstb.1999.0449","article-title":"Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease","volume":"354","author":"Cha","year":"1999","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"11","key":"10.1016\/j.pharmthera.2010.07.008_bb0245","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1073\/pnas.95.11.6480","article-title":"Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene","volume":"95","author":"Cha","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0250","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.nbd.2007.07.028","article-title":"Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo","volume":"29","author":"Charvin","year":"2008","journal-title":"Neurobiol Dis"},{"issue":"34","key":"10.1016\/j.pharmthera.2010.07.008_bb0255","doi-asserted-by":"crossref","first-page":"12218","DOI":"10.1073\/pnas.0502698102","article-title":"Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation","volume":"102","author":"Charvin","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.pharmthera.2010.07.008_bb0260","doi-asserted-by":"crossref","first-page":"RC143","DOI":"10.1523\/JNEUROSCI.21-10-j0001.2001","article-title":"Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease","volume":"21","author":"Chen","year":"2001","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0265","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1006\/jmbi.2001.4850","article-title":"Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity","volume":"311","author":"Chen","year":"2001","journal-title":"J Mol Biol"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb0270","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.febslet.2008.01.028","article-title":"D2\/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways","volume":"582","author":"Chen","year":"2008","journal-title":"FEBS Lett"},{"issue":"16","key":"10.1016\/j.pharmthera.2010.07.008_bb0275","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1093\/hmg\/ddp230","article-title":"The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin\u2013proteasome system","volume":"18","author":"Chiang","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0280","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0304-3940(01)02258-3","article-title":"Group I metabotropic glutamate receptors control phosphorylation of CREB, Elk-1 and ERK via a CaMKII-dependent pathway in rat striatum","volume":"313","author":"Choe","year":"2001","journal-title":"Neurosci Lett"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0285","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1471-4159.2005.03029.x","article-title":"CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model","volume":"93","author":"Chou","year":"2005","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0290","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.expneurol.2008.05.015","article-title":"Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice","volume":"213","author":"Cipriani","year":"2008","journal-title":"Exp Neurol"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb0295","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/hmg\/7.5.783","article-title":"Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture","volume":"7","author":"Cooper","year":"1998","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb0300","first-page":"426","article-title":"Acetylcholine replacement therapy in the menagement of huntington's disease","volume":"135","author":"Corbascio","year":"1981","journal-title":"West J Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0305","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/archneur.1978.00500250031006","article-title":"Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor","volume":"35","author":"Corsini","year":"1978","journal-title":"Arch Neurol"},{"issue":"15","key":"10.1016\/j.pharmthera.2010.07.008_bb0310","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A pilot study using nabilone for symptomatic treatment in Huntington's disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0315","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/jnp.2006.18.4.553","article-title":"Nabilone could treat chorea and irritability in Huntington's disease","volume":"18","author":"Curtis","year":"2006","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"14","key":"10.1016\/j.pharmthera.2010.07.008_bb0320","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1096\/fj.06-6533fje","article-title":"Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin","volume":"20","author":"Cyr","year":"2006","journal-title":"FASEB J"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0325","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1046\/j.1471-4159.2001.00435.x","article-title":"Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways","volume":"78","author":"D'Onofrio","year":"2001","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0330","first-page":"23","article-title":"Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis","volume":"13","author":"Davis","year":"1978","journal-title":"Biol Psychiatry"},{"issue":"9","key":"10.1016\/j.pharmthera.2010.07.008_bb0335","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1523\/JNEUROSCI.22-09-03473.2002","article-title":"Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length","volume":"22","author":"de Almeida","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.07.008_bb0340","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/scientificamerican0563-64","article-title":"The lysosome","volume":"208","author":"De Duve","year":"1963","journal-title":"Sci Am"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0345","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.euroneuro.2005.06.001","article-title":"UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay\/arrest the progression of different motor-related disorders","volume":"16","author":"de Lago","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2010.07.008_bb0350","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.brainres.2005.05.024","article-title":"Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease","volume":"1050","author":"de Lago","year":"2005","journal-title":"Brain Res"},{"issue":"23","key":"10.1016\/j.pharmthera.2010.07.008_bb0355","doi-asserted-by":"crossref","first-page":"16147","DOI":"10.1074\/jbc.M601467200","article-title":"Optineurin increases cell survival and translocates to the nucleus in a Rab8-dependent manner upon an apoptotic stimulus","volume":"281","author":"De Marco","year":"2006","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0360","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1523\/JNEUROSCI.23-06-02371.2003","article-title":"Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus","volume":"23","author":"Derkinderen","year":"2003","journal-title":"J Neurosci"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.07.008_bb0365","doi-asserted-by":"crossref","first-page":"e8287","DOI":"10.1371\/journal.pone.0008287","article-title":"Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho\/ROCK-II activation","volume":"4","author":"Deyts","year":"2009","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0370","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0163-7258(98)00042-4","article-title":"The role of excitotoxicity in neurodegenerative disease: implications for therapy","volume":"81","author":"Doble","year":"1999","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0375","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nbd.2007.07.009","article-title":"Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6\/2 Huntington's disease mice","volume":"28","author":"Domenici","year":"2007","journal-title":"Neurobiol Dis"},{"issue":"9634","key":"10.1016\/j.pharmthera.2010.07.008_bb0380","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2010.07.008_bb0385","doi-asserted-by":"crossref","unstructured":"Dowie, M. J., Howard, M. L., Nicholson, L. F., Faull, R. L., Hannan, A. J., & Glass, M. (2010). Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neuroscience. doi:10.1016\/j.neuroscience.2010.06.056","DOI":"10.1016\/j.neuroscience.2010.06.056"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0390","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.20075","article-title":"Paroxetine retards disease onset and progression in Huntingtin mutant mice","volume":"55","author":"Duan","year":"2004","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0395","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3390\/molecules15031168","article-title":"Control of intracellular calcium signaling as a neuroprotective strategy","volume":"15","author":"Duncan","year":"2010","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.07.008_bb0400","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.cellsig.2005.05.020","article-title":"The regulatory mechanisms of export trafficking of G protein-coupled receptors","volume":"17","author":"Duvernay","year":"2005","journal-title":"Cell Signal"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0405","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ng0893-387","article-title":"Trinucleotide repeat length instability and age of onset in Huntington's disease","volume":"4","author":"Duyao","year":"1993","journal-title":"Nat Genet"},{"issue":"24","key":"10.1016\/j.pharmthera.2010.07.008_bb0410","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJM197606102942402","article-title":"Huntington's chorea. Changes in neurotransmitter receptors in the brain","volume":"294","author":"Enna","year":"1976","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.pharmthera.2010.07.008_bb0415","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1523\/JNEUROSCI.4356-06.2007","article-title":"Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease","volume":"27","author":"Fan","year":"2007","journal-title":"J Neurosci"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0420","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/WNF.0b013e318166da60","article-title":"The long-term effect of tetrabenazine in the management of Huntington disease","volume":"31","author":"Fasano","year":"2008","journal-title":"Clin Neuropharmacol"},{"issue":"4725","key":"10.1016\/j.pharmthera.2010.07.008_bb0425","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1126\/science.2931802","article-title":"Selective sparing of a class of striatal neurons in Huntington's disease","volume":"230","author":"Ferrante","year":"1985","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0430","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0922-4106(93)90157-5","article-title":"Opposing actions of an adenosine A2 receptor agonist and a GTP analogue on the regulation of dopamine D2 receptors in rat neostriatal membranes","volume":"244","author":"Ferre","year":"1993","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0435","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1046\/j.1471-4159.2003.02145.x","article-title":"Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage","volume":"88","author":"Fink","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.07.008_bb0440","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1192\/bjp.149.5.654","article-title":"Treatment of depression in Huntington's disease with monoamine oxidase inhibitors","volume":"149","author":"Ford","year":"1986","journal-title":"Br J Psychiatry"},{"issue":"5576","key":"10.1016\/j.pharmthera.2010.07.008_bb0445","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1126\/science.1073845","article-title":"Neurodegeneration. A glutamine-rich trail leads to transcription factors","volume":"296","author":"Freiman","year":"2002","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0450","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1523\/JNEUROSCI.22-06-02174.2002","article-title":"The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase\/c-Jun module","volume":"22","author":"Garcia","year":"2002","journal-title":"J Neurosci"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2010.07.008_bb0455","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0162-3109(00)80302-1","article-title":"Complement components of the innate immune system in health and disease in the CNS","volume":"49","author":"Gasque","year":"2000","journal-title":"Immunopharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0460","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/SHK.0b013e3181a20792","article-title":"The selective adenosine A2A receptor agonist CGS 21680 reduces JNK MAPK activation in oligodendrocytes in injured spinal cord","volume":"32","author":"Genovese","year":"2009","journal-title":"Shock"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0465","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.nbd.2009.02.014","article-title":"Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease","volume":"34","author":"Giampa","year":"2009","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0470","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nbd.2004.05.008","article-title":"Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow","volume":"17","author":"Gianfriddo","year":"2004","journal-title":"Neurobiol Dis"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb0475","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/hmg\/ddg046","article-title":"Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice","volume":"12","author":"Gines","year":"2003","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb0480","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/hmg\/ddg046","article-title":"Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice","volume":"12","author":"Gines","year":"2003","journal-title":"Hum Mol Genet"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.07.008_bb1600","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1074\/jbc.M708192200","article-title":"Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment","volume":"283","author":"Giorgini","year":"2008","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0485","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"issue":"14","key":"10.1016\/j.pharmthera.2010.07.008_bb0490","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1523\/JNEUROSCI.17-14-05327.1997","article-title":"Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor","volume":"17","author":"Glass","year":"1997","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0495","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0306-4522(03)00595-5","article-title":"Delayed onset of Huntington's Disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors","volume":"123","author":"Glass","year":"2004","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0500","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.molcel.2004.09.016","article-title":"A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease","volume":"15","author":"Goehler","year":"2004","journal-title":"Mol Cell"},{"issue":"42","key":"10.1016\/j.pharmthera.2010.07.008_bb0505","doi-asserted-by":"crossref","first-page":"39594","DOI":"10.1074\/jbc.C200353200","article-title":"Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons","volume":"277","author":"Goffredo","year":"2002","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0510","doi-asserted-by":"crossref","first-page":"e5292","DOI":"10.1371\/journal.pone.0005292","article-title":"Short-term striatal gene expression responses to brain-derived neurotrophic factor are dependent on MEK and ERK activation","volume":"4","author":"Gokce","year":"2009","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0515","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ng0896-442","article-title":"Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract","volume":"13","author":"Goldberg","year":"1996","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0520","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1460-9568.1999.00453.x","article-title":"Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases","volume":"11","author":"Goodchild","year":"1999","journal-title":"Eur J Neurosci"},{"issue":"4688","key":"10.1016\/j.pharmthera.2010.07.008_bb0525","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.3155875","article-title":"Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease","volume":"227","author":"Graveland","year":"1985","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.pharmthera.2010.07.008_bb0530","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","article-title":"Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice","volume":"28","author":"Gray","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.07.008_bb0535","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0074-7742(07)82002-2","article-title":"Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins","volume":"82","author":"Griffiths","year":"2007","journal-title":"Int Rev Neurobiol"},{"issue":"8","key":"10.1016\/j.pharmthera.2010.07.008_bb0540","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/j.1460-9568.2005.04365.x","article-title":"Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine","volume":"22","author":"Grote","year":"2005","journal-title":"Eur J Neurosci"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb0545","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.410010503","article-title":"Huntington's disease: clinical and chemical effects of choline administration","volume":"1","author":"Growdon","year":"1977","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb1590","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","article-title":"Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease","volume":"17","author":"Guidetti","year":"2004","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb1595","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2006.02.011","article-title":"Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice","volume":"2","author":"Guidetti","year":"2006","journal-title":"Neurobiol Dis"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.07.008_bb0550","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","article-title":"Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology","volume":"19","author":"Gutekunst","year":"1999","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0555","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbr.2008.03.020","article-title":"Molecular biology of 5-HT receptors","volume":"195","author":"Hannon","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2010.07.008_bb0560","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1146\/annurev.pharmtox.48.113006.094830","article-title":"Regulation of GPCRs by endocytic membrane trafficking and its potential implications","volume":"48","author":"Hanyaloglu","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.pharmthera.2010.07.008_bb0565","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0968-0004(03)00168-3","article-title":"The hunt for huntingtin function: interaction partners tell many different stories","volume":"28","author":"Harjes","year":"2003","journal-title":"Trends Biochem Sci"},{"issue":"50","key":"10.1016\/j.pharmthera.2010.07.008_bb0570","doi-asserted-by":"crossref","first-page":"21377","DOI":"10.1073\/pnas.0903676106","article-title":"Calcium signaling cascade links dopamine D1\u2013D2 receptor heteromer to striatal BDNF production and neuronal growth","volume":"106","author":"Hasbi","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0575","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd2784","article-title":"Tetrabenazine","volume":"8","author":"Hayden","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0580","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0006-8993(81)90853-2","article-title":"Cholecystokinin receptors are decreased in basal ganglia and cerebral cortex of Huntington's disease","volume":"225","author":"Hays","year":"1981","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0585","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/1096-9861(20010312)431:3<331::AID-CNE1074>3.0.CO;2-W","article-title":"Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum","volume":"431","author":"Hettinger","year":"2001","journal-title":"J Comp Neurol"},{"issue":"42","key":"10.1016\/j.pharmthera.2010.07.008_bb0590","doi-asserted-by":"crossref","first-page":"10916","DOI":"10.1523\/JNEUROSCI.3269-06.2006","article-title":"Inositol 1, 4, 5-trisphosphate receptor type 1 in granule cells, not in Purkinje cells, regulates the dendritic morphology of Purkinje cells through brain-derived neurotrophic factor production","volume":"26","author":"Hisatsune","year":"2006","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0595","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S0033291799002871","article-title":"The molecular biology of Huntington's disease","volume":"31","author":"Ho","year":"2001","journal-title":"Psychol Med"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0600","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0605","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/hmg\/ddl013","article-title":"Regional and cellular gene expression changes in human Huntington's disease brain","volume":"15","author":"Hodges","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0610","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","article-title":"A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration","volume":"23","author":"Hodgson","year":"1999","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.pharmthera.2010.07.008_bb0615","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00702-006-0514-6","article-title":"Huntingtin interacts with the receptor sorting family protein GASP2","volume":"113","author":"Horn","year":"2006","journal-title":"J Neural Transm"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0620","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/exnr.1996.6374","article-title":"Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death","volume":"143","author":"Hoyt","year":"1997","journal-title":"Exp Neurol"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0625","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/B:SCAM.0000007124.19463.e5","article-title":"Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins","volume":"24","author":"Huang","year":"1998","journal-title":"Somat Cell Mol Genet"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0630","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"Huntington's Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.pharmthera.2010.07.008_bb0635","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","article-title":"Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study","volume":"61","author":"Huntington Study Group","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0640","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001756-200303240-00007","article-title":"Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation","volume":"14","author":"Igarashi","year":"2003","journal-title":"NeuroReport"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0645","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0896-6273(00)80573-5","article-title":"Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons","volume":"21","author":"Jackson","year":"1998","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0650","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1009666707307","article-title":"Adenosine-induced cell death: evidence for receptor-mediated signalling","volume":"4","author":"Jacobson","year":"1999","journal-title":"Apoptosis"},{"issue":"10","key":"10.1016\/j.pharmthera.2010.07.008_bb0655","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/hmg\/10.10.1049","article-title":"Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release","volume":"10","author":"Jana","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0660","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1212\/WNL.38.3.391","article-title":"Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias","volume":"38","author":"Jankovic","year":"1988","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0665","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.parkreldis.2008.12.006","article-title":"Adenosine, adenosine A 2A antagonists, and Parkinson's disease","volume":"15","author":"Jenner","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.07.008_bb0670","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1091\/mbc.E08-12-1249","article-title":"ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery","volume":"20","author":"Jung","year":"2009","journal-title":"Mol Biol Cell"},{"issue":"20","key":"10.1016\/j.pharmthera.2010.07.008_bb0675","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.96.20.11404","article-title":"Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells","volume":"96","author":"Kazantsev","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"20","key":"10.1016\/j.pharmthera.2010.07.008_bb0680","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.96.20.11404","article-title":"Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells","volume":"96","author":"Kazantsev","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0685","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0165-6147(00)89020-3","article-title":"Agonist-receptor efficacy. I: Mechanisms of efficacy and receptor promiscuity","volume":"16","author":"Kenakin","year":"1995","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.07.008_bb0690","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0165-6147(03)00167-6","article-title":"Ligand-selective receptor conformations revisited: the promise and the problem","volume":"24","author":"Kenakin","year":"2003","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.07.008_bb0695","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/j.1460-9568.2004.03285.x","article-title":"Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity","volume":"19","author":"Khaspekov","year":"2004","journal-title":"Eur J Neurosci"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0700","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archneurol.2009.334","article-title":"A randomized, placebo-controlled trial of latrepirdine in Huntington disease","volume":"67","author":"Kieburtz","year":"2010","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0705","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0306-4522(98)00400-X","article-title":"Forskolin and dopamine D1 receptor activation increase huntingtin's association with endosomes in immortalized neuronal cells of striatal origin","volume":"89","author":"Kim","year":"1999","journal-title":"Neuroscience"},{"issue":"22","key":"10.1016\/j.pharmthera.2010.07.008_bb0710","doi-asserted-by":"crossref","first-page":"12784","DOI":"10.1073\/pnas.221451398","article-title":"Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis","volume":"98","author":"Kim","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"34","key":"10.1016\/j.pharmthera.2010.07.008_bb0715","doi-asserted-by":"crossref","first-page":"12736","DOI":"10.1073\/pnas.0401860101","article-title":"Huntingtin-associated protein 1 regulates inhibitory synaptic transmission by modulating gamma-aminobutyric acid type A receptor membrane trafficking","volume":"101","author":"Kittler","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0720","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbr.2006.01.003","article-title":"Behaviour changes in a transgenic model of Huntington's disease","volume":"169","author":"Klivenyi","year":"2006","journal-title":"Behav Brain Res"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0725","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1531-8249(199912)46:6<842::AID-ANA6>3.0.CO;2-O","article-title":"Huntington aggregates may not predict neuronal death in Huntington's disease","volume":"46","author":"Kuemmerle","year":"1999","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0730","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s12031-008-9093-3","article-title":"Somatostatin in medium-sized aspiny interneurons of striatum is responsible for their preservation in quinolinic acid and N-methyl-d-asparate-induced neurotoxicity","volume":"35","author":"Kumar","year":"2008","journal-title":"J Mol Neurosci"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0735","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington's disease: a 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0740","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00001756-200305060-00007","article-title":"Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate","volume":"14","author":"Lastres-Becker","year":"2003","journal-title":"NeuroReport"},{"issue":"15","key":"10.1016\/j.pharmthera.2010.07.008_bb0745","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1097\/00001756-200410250-00015","article-title":"Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo","volume":"15","author":"Lastres-Becker","year":"2004","journal-title":"NeuroReport"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb0750","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1046\/j.1471-4159.2003.01595.x","article-title":"Compounds acting at the endocannabinoid and\/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease","volume":"84","author":"Lastres-Becker","year":"2003","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0755","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/syn.10054","article-title":"Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease","volume":"44","author":"Lastres-Becker","year":"2002","journal-title":"Synapse"},{"issue":"52","key":"10.1016\/j.pharmthera.2010.07.008_bb0760","doi-asserted-by":"crossref","first-page":"19144","DOI":"10.1073\/pnas.0509588102","article-title":"The cannabinoid agonist WIN55, 212\u20132 increases intracellular calcium via CB1 receptor coupling to Gq\/11 G proteins","volume":"102","author":"Lauckner","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.pharmthera.2010.07.008_bb0765","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.tips.2007.06.004","article-title":"Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology","volume":"28","author":"Leach","year":"2007","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0770","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1073\/pnas.061020198","article-title":"Activation of Trk neurotrophin receptors in the absence of neurotrophins","volume":"98","author":"Lee","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb0775","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/MCB.22.5.1277-1287.2002","article-title":"Interaction of Huntington disease protein with transcriptional activator Sp1","volume":"22","author":"Li","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0780","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tig.2004.01.008","article-title":"Huntingtin\u2013protein interactions and the pathogenesis of Huntington's disease","volume":"20","author":"Li","year":"2004","journal-title":"Trends Genet"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0785","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/hmg\/ddm360","article-title":"AKT-sensitive or insensitive pathways of toxicity in glial cells and neurons in Drosophila models of Huntington's disease","volume":"17","author":"Lievens","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0790","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/hmg\/10.2.137","article-title":"Neurological abnormalities in a knock-in mouse model of Huntington's disease","volume":"10","author":"Lin","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"44","key":"10.1016\/j.pharmthera.2010.07.008_bb0795","doi-asserted-by":"crossref","first-page":"28873","DOI":"10.1074\/jbc.273.44.28873","article-title":"Expression of polyglutamine-expanded huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line","volume":"273","author":"Liu","year":"1998","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0800","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2174\/138161209787315639","article-title":"Design of multivalent ligand targeting G-protein-coupled receptors","volume":"15","author":"Liu","year":"2009","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1016\/j.pharmthera.2010.07.008_bb0805","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/hmg\/7.9.1355","article-title":"A cellular model that recapitulates major pathogenic steps of Huntington's disease","volume":"7","author":"Lunkes","year":"1998","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0810","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1046\/j.1471-4159.1998.71030980.x","article-title":"D2 dopamine receptors stimulate mitogenesis through pertussis toxin-sensitive G proteins and Ras-involved ERK and SAP\/JNK pathways in rat C6-D2L glioma cells","volume":"71","author":"Luo","year":"1998","journal-title":"J Neurochem"},{"issue":"9","key":"10.1016\/j.pharmthera.2010.07.008_bb0815","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/hmg\/9.9.1259","article-title":"Decreased expression of striatal signaling genes in a mouse model of Huntington's disease","volume":"9","author":"Luthi-Carter","year":"2000","journal-title":"Hum Mol Genet"},{"issue":"5\u20136","key":"10.1016\/j.pharmthera.2010.07.008_bb0820","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.pneurobio.2006.11.006","article-title":"The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases","volume":"81","author":"Maccarrone","year":"2007","journal-title":"Prog Neurobiol"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0825","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0830","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1212\/WNL.54.2.452","article-title":"Rate of functional decline in Huntington's disease. Huntington Study Group","volume":"54","author":"Marder","year":"2000","journal-title":"Neurology"},{"issue":"5642","key":"10.1016\/j.pharmthera.2010.07.008_bb0835","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","article-title":"CB1 cannabinoid receptors and on-demand defense against excitotoxicity","volume":"302","author":"Marsicano","year":"2003","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0840","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1006\/exnr.1998.6942","article-title":"Neuroprotective effects of the alpha2-adrenoceptor antagonists, (+)-efaroxan and (+\/\u2212)-idazoxan, against quinolinic acid-induced lesions of the rat striatum","volume":"154","author":"Martel","year":"1998","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0845","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s007260070055","article-title":"Drug treatments to reduce excitotoxicity in vivo: a potential for alpha2-adrenoceptor antagonists?","volume":"19","author":"Martel","year":"2000","journal-title":"Amino Acids"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0850","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/syn.890150306","article-title":"Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models","volume":"15","author":"Martinez-Mir","year":"1993","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0855","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neulet.2007.02.034","article-title":"Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice","volume":"417","author":"Martire","year":"2007","journal-title":"Neurosci Lett"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0860","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0304-3940(95)12137-S","article-title":"Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission","volume":"201","author":"Mary","year":"1995","journal-title":"Neurosci Lett"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0865","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/14728210902918299","article-title":"Emerging drug therapies in Huntington's disease","volume":"14","author":"Mason","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"issue":"6312","key":"10.1016\/j.pharmthera.2010.07.008_bb0870","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/349760a0","article-title":"Sequence and expression of a metabotropic glutamate receptor","volume":"349","author":"Masu","year":"1991","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0875","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/1055-8330(95)90016-0","article-title":"An endogenous dopaminergic neurotoxin: implication for Parkinson's disease","volume":"4","author":"Mattammal","year":"1995","journal-title":"Neurodegeneration"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0880","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0014-4886(80)90218-6","article-title":"Ethanol, baclofen, and kainic acid neurotoxicity","volume":"69","author":"McGeer","year":"1980","journal-title":"Exp Neurol"},{"issue":"9","key":"10.1016\/j.pharmthera.2010.07.008_bb0885","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.23.9.912","article-title":"Choline acetylase and glutamic acid decarboxylase in Huntington's chorea. A preliminary study","volume":"23","author":"McGeer","year":"1973","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0890","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1046\/j.1471-4159.1998.70062406.x","article-title":"Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor","volume":"70","author":"McLaughlin","year":"1998","journal-title":"J Neurochem"},{"issue":"Pt 6","key":"10.1016\/j.pharmthera.2010.07.008_bb0895","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/brain\/awp076","article-title":"Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia","volume":"132","author":"Melani","year":"2009","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb0900","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J Comp Neurol"},{"issue":"13","key":"10.1016\/j.pharmthera.2010.07.008_bb0905","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1093\/emboj\/cdg334","article-title":"Disruption of the endocytic protein HIP1 results in neurological deficits and decreased AMPA receptor trafficking","volume":"22","author":"Metzler","year":"2003","journal-title":"EMBO J"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb0910","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.phrs.2007.09.008","article-title":"Endocannabinoids and neurodegenerative diseases","volume":"56","author":"Micale","year":"2007","journal-title":"Pharmacol Res"},{"issue":"17","key":"10.1016\/j.pharmthera.2010.07.008_bb0915","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1097\/00001756-199812010-00034","article-title":"Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats","volume":"9","author":"Monopoli","year":"1998","journal-title":"NeuroReport"},{"issue":"18","key":"10.1016\/j.pharmthera.2010.07.008_bb0920","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.83.18.6682","article-title":"Identification of a cyclic-AMP-responsive element within the rat somatostatin gene","volume":"83","author":"Montminy","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0925","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF03033210","article-title":"Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease","volume":"3","author":"Morelli","year":"2001","journal-title":"Neurotox Res"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0930","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1247\/csf.29.101","article-title":"Adenosine A2A receptor facilitates calcium-dependent protein secretion through the activation of protein kinase A and phosphatidylinositol-3 kinase in PC12 cells","volume":"29","author":"Mori","year":"2004","journal-title":"Cell Struct Funct"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0935","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0165-5728(99)00261-1","article-title":"The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease","volume":"105","author":"Mukherjee","year":"2000","journal-title":"J Neuroimmunol"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb0940","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/1531-8257(199911)14:6<1038::AID-MDS1024>3.0.CO;2-7","article-title":"Nabilone increases choreatic movements in Huntington's disease","volume":"14","author":"Muller-Vahl","year":"1999","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0945","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mrdd.1022","article-title":"Juvenile onset Huntington's disease\u2014clinical and research perspectives","volume":"7","author":"Nance","year":"2001","journal-title":"Ment Retard Dev Disabil Res Rev"},{"issue":"4614","key":"10.1016\/j.pharmthera.2010.07.008_bb0950","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1126\/science.6136092","article-title":"Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia","volume":"221","author":"Nemeroff","year":"1983","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb0955","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrd747","article-title":"Regulators of G-protein signalling as new central nervous system drug targets","volume":"1","author":"Neubig","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2010.07.008_bb0960","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"10.1016\/j.pharmthera.2010.07.008_bb0965","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrn1970","article-title":"Enriched environments, experience-dependent plasticity and disorders of the nervous system","volume":"7","author":"Nithianantharajah","year":"2006","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0970","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0306-4522(95)00596-X","article-title":"Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease","volume":"72","author":"Norris","year":"1996","journal-title":"Neuroscience"},{"issue":"5512","key":"10.1016\/j.pharmthera.2010.07.008_bb0975","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","article-title":"Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity","volume":"291","author":"Nucifora","year":"2001","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.07.008_bb0980","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1212\/WNL.33.7.932","article-title":"Effect of cholinergic agents in Huntington's disease: a reappraisal","volume":"33","author":"Nutt","year":"1983","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.07.008_bb0985","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nrd2199","article-title":"How many drug targets are there?","volume":"5","author":"Overington","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb0990","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1083\/jcb.200509091","article-title":"Huntingtin-HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington's disease","volume":"172","author":"Pal","year":"2006","journal-title":"J Cell Biol"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb0995","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0006-8993(90)91481-U","article-title":"Reduced density of striatal somatostatin receptors in Huntington's chorea","volume":"522","author":"Palacios","year":"1990","journal-title":"Brain Res"},{"issue":"Pt 11","key":"10.1016\/j.pharmthera.2010.07.008_bb1000","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb1005","first-page":"545","article-title":"Tetrabenazine in the treatment of Huntington's disease","volume":"3","author":"Paleacu","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"10.1016\/j.pharmthera.2010.07.008_bb1010","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/sj.mt.6300185","article-title":"Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates","volume":"15","author":"Palfi","year":"2007","journal-title":"Mol Ther"},{"issue":"23\u201324","key":"10.1016\/j.pharmthera.2010.07.008_bb1015","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.drudis.2008.09.002","article-title":"Physiological relevance of GPCR oligomerization and its impact on drug discovery","volume":"13","author":"Panetta","year":"2008","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb1020","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/hmg\/ddn385","article-title":"Altered serotonin receptor expression is associated with depression-related behavior in the R6\/1 transgenic mouse model of Huntington's disease","volume":"18","author":"Pang","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10.1016\/j.pharmthera.2010.07.008_bb1025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nn884","article-title":"Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines","volume":"5","author":"Panov","year":"2002","journal-title":"Nat Neurosci"},{"issue":"23","key":"10.1016\/j.pharmthera.2010.07.008_bb1030","doi-asserted-by":"crossref","first-page":"13318","DOI":"10.1073\/pnas.231476398","article-title":"Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death","volume":"98","author":"Parker","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb1035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10401239609149087","article-title":"l-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease","volume":"8","author":"Patel","year":"1996","journal-title":"Ann Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb1040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2007.10.015","article-title":"The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6\/2 Huntington's disease mouse model","volume":"210","author":"Peng","year":"2008","journal-title":"Exp Neurol"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb1045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mds.870050202","article-title":"Huntington's disease in Venezuela: 7years of follow-up on symptomatic and asymptomatic individuals","volume":"5","author":"Penney","year":"1990","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb1050","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nbd.2005.10.009","article-title":"Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons","volume":"22","author":"Picconi","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pharmthera.2010.07.008_bb1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2006.06.013","article-title":"The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum","author":"Pintor","year":"2006","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb1060","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000117158","article-title":"Proglumide, a cholecystokinin receptor antagonist, reduces neuroleptic action in Huntington's chorea","volume":"35","author":"Piolti","year":"1995","journal-title":"Eur Neurol"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb1065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s007260070040","article-title":"Cell-type specificity of mGluR activation in striatal neuronal subtypes","volume":"19","author":"Pisani","year":"2000","journal-title":"Amino Acids"},{"issue":"10","key":"10.1016\/j.pharmthera.2010.07.008_bb1070","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tins.2007.07.008","article-title":"Re-emergence of striatal cholinergic interneurons in movement disorders","volume":"30","author":"Pisani","year":"2007","journal-title":"Trends Neurosci"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb1075","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/sj.bjp.0700999","article-title":"Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones","volume":"120","author":"Pisani","year":"1997","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb1080","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0896-6273(03)00697-4","article-title":"A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor","volume":"40","author":"Pollitt","year":"2003","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb1085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0014-2999(95)00679-6","article-title":"Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats","volume":"287","author":"Popoli","year":"1995","journal-title":"Eur J Pharmacol"},{"issue":"5\u20136","key":"10.1016\/j.pharmthera.2010.07.008_bb1090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.pneurobio.2006.12.005","article-title":"Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease","volume":"81","author":"Popoli","year":"2007","journal-title":"Prog Neurobiol"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb1095","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1523\/JNEUROSCI.22-05-01967.2002","article-title":"Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum","volume":"22","author":"Popoli","year":"2002","journal-title":"J Neurosci"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb1100","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1471-4159.2004.02448.x","article-title":"Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid-induced striatal toxicity: involvement of pre- and post-synaptic mechanisms and lack of direct NMDA blocking activity","volume":"89","author":"Popoli","year":"2004","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb1105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11302-007-9066-y","article-title":"Adenosine A(2A) receptors modulate BDNF both in normal conditions and in experimental models of Huntington's disease","volume":"3","author":"Potenza","year":"2007","journal-title":"Purinergic Signal"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.07.008_bb1110","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/mds.22188","article-title":"A Europe-wide assessment of current medication choices in Huntington's disease","volume":"23","author":"Priller","year":"2008","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.pharmthera.2010.07.008_bb1115","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp.47.8.844","article-title":"A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia","volume":"47","author":"Quinn","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb1120","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S1535-6108(03)00107-7","article-title":"Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells","volume":"3","author":"Rao","year":"2003","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb1125","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","article-title":"Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease","volume":"36","author":"Ravikumar","year":"2004","journal-title":"Nat Genet"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2010.07.008_bb1130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0006-8993(99)01489-4","article-title":"The intrastratial injection of an adenosine A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease","volume":"831","author":"Reggio","year":"1999","journal-title":"Brain Res"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.07.008_bb1135","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1091\/mbc.E05-07-0629","article-title":"The actin cytoskeleton is required for selective types of autophagy, but not nonspecific autophagy, in the yeast Saccharomyces cerevisiae","volume":"16","author":"Reggiori","year":"2005","journal-title":"Mol Biol Cell"},{"issue":"10","key":"10.1016\/j.pharmthera.2010.07.008_bb1140","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s004150170085","article-title":"Wild-type huntingtin up-regulates BDNF transcription in Huntington's disease","volume":"248","author":"Reilly","year":"2001","journal-title":"J Neurol"},{"issue":"15","key":"10.1016\/j.pharmthera.2010.07.008_bb1145","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","article-title":"Differential loss of striatal projection neurons in Huntington disease","volume":"85","author":"Reiner","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb1150","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.neuroscience.2008.02.052","article-title":"Dopamine D1 receptor-mediated aggregation of N-terminal fragments of mutant huntingtin and cell death in a neuroblastoma cell line","volume":"153","author":"Robinson","year":"2008","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb1155","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q","article-title":"Riluzole therapy in Huntington's disease (HD)","volume":"14","author":"Rosas","year":"1999","journal-title":"Mov Disord"},{"issue":"Pt 4","key":"10.1016\/j.pharmthera.2010.07.008_bb1160","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/brain\/awn025","article-title":"Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity","volume":"131","author":"Rosas","year":"2008","journal-title":"Brain"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2010.07.008_bb1165","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1566-2772(00)00014-1","article-title":"Huntington's disease","volume":"1","author":"Ross","year":"2001","journal-title":"Clin Neurosci Res"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb1170","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1128\/MMBR.68.2.320-344.2004","article-title":"ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions","volume":"68","author":"Roux","year":"2004","journal-title":"Microbiol Mol Biol Rev"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb1175","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1096\/fj.07-9814","article-title":"Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death","volume":"22","author":"Roze","year":"2008","journal-title":"FASEB J"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.07.008_bb1180","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/hmg\/ddh082","article-title":"Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway","volume":"13","author":"Ruan","year":"2004","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb1185","first-page":"16","article-title":"Phenotypic characterization of individuals with 30\u201340 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36\u201339 repeats","volume":"59","author":"Rubinsztein","year":"1996","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb1190","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1124\/mol.58.4.814","article-title":"The CB1 cannabinoid receptor is coupled to the activation of c-jun N-terminal kinase","volume":"58","author":"Rueda","year":"2000","journal-title":"Mol Pharmacol"},{"issue":"39","key":"10.1016\/j.pharmthera.2010.07.008_bb1195","doi-asserted-by":"crossref","first-page":"9723","DOI":"10.1523\/JNEUROSCI.3044-08.2008","article-title":"Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry","volume":"28","author":"Runne","year":"2008","journal-title":"J Neurosci"},{"issue":"11","key":"10.1016\/j.pharmthera.2010.07.008_bb1200","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/hmg\/ddm078","article-title":"Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models","volume":"16","author":"Sadri-Vakili","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"11","key":"10.1016\/j.pharmthera.2010.07.008_bb1205","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/glia.20838","article-title":"Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease","volume":"57","author":"Sagredo","year":"2009","journal-title":"Glia"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb1210","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","article-title":"Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors","volume":"26","author":"Sagredo","year":"2007","journal-title":"Eur J Neurosci"},{"issue":"6921","key":"10.1016\/j.pharmthera.2010.07.008_bb1215","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature01301","article-title":"Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders","volume":"421","author":"Sanchez","year":"2003","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb1220","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0306-4522(94)00427-7","article-title":"Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis","volume":"64","author":"Sapp","year":"1995","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb1225","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0092-8674(00)81782-1","article-title":"Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions","volume":"95","author":"Saudou","year":"1998","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb1230","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bbr.2006.10.004","article-title":"Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease","volume":"176","author":"Scattoni","year":"2007","journal-title":"Behav Brain Res"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb1235","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/sj.onc.1207278","article-title":"Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion","volume":"23","author":"Schafer","year":"2004","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.pharmthera.2010.07.008_bb1240","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.bcp.2009.06.021","article-title":"Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities","volume":"78","author":"Schaffhauser","year":"2009","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb1245","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/mds.10229","article-title":"Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease","volume":"17","author":"Schiefer","year":"2002","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2010.07.008_bb1250","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.brainres.2004.06.005","article-title":"The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease","volume":"1019","author":"Schiefer","year":"2004","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb1255","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","article-title":"Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin","volume":"8","author":"Schilling","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb1260","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/mol.58.3.477","article-title":"Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1\/2","volume":"58","author":"Schulte","year":"2000","journal-title":"Mol Pharmacol"},{"issue":"4582","key":"10.1016\/j.pharmthera.2010.07.008_bb1265","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.6849138","article-title":"Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain","volume":"219","author":"Schwarcz","year":"1983","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb1270","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1476-5381.2010.00735.x","article-title":"The endocannabinoid system as a target for the treatment of neurodegenerative disease","volume":"160","author":"Scotter","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb1275","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1476-5381.2010.00773.x","article-title":"Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease","volume":"160","author":"Scotter","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"10 Suppl","key":"10.1016\/j.pharmthera.2010.07.008_bb1280","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S1471-1931(00)00025-2","article-title":"Dopamine receptors: from structure to behavior","volume":"23","author":"Sealfon","year":"2000","journal-title":"Trends Neurosci"},{"issue":"10","key":"10.1016\/j.pharmthera.2010.07.008_bb1285","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s004150170071","article-title":"Riluzole in Huntington's disease (HD): an open label study with one year follow up","volume":"248","author":"Seppi","year":"2001","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.07.008_bb1290","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.febslet.2008.04.009","article-title":"ROCK and PRK-2 mediate the inhibitory effect of Y-27632 on polyglutamine aggregation","volume":"582","author":"Shao","year":"2008","journal-title":"FEBS Lett"},{"issue":"17","key":"10.1016\/j.pharmthera.2010.07.008_bb1295","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1128\/MCB.00079-08","article-title":"Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation","volume":"28","author":"Shao","year":"2008","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb1300","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ana.410250308","article-title":"A controlled clinical trial of baclofen as protective therapy in early Huntington's disease","volume":"25","author":"Shoulson","year":"1989","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.pharmthera.2010.07.008_bb1305","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1212\/WNL.36.8.1099","article-title":"Huntington's disease: effect of cysteamine, a somatostatin-depleting agent","volume":"36","author":"Shults","year":"1986","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb1310","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1006\/exnr.1998.7005","article-title":"Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein","volume":"156","author":"Sieradzan","year":"1999","journal-title":"Exp Neurol"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb1315","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1006\/exnr.1999.7170","article-title":"Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease","volume":"159","author":"Singhrao","year":"1999","journal-title":"Exp Neurol"},{"issue":"4414","key":"10.1016\/j.pharmthera.2010.07.008_bb1320","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1126\/science.482929","article-title":"Dopamine auto- and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists","volume":"206","author":"Skirboll","year":"1979","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.pharmthera.2010.07.008_bb1325","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1093\/hmg\/ddl252","article-title":"Cholinergic neuronal defect without cell loss in Huntington's disease","volume":"15","author":"Smith","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"18","key":"10.1016\/j.pharmthera.2010.07.008_bb1330","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1021\/jm900298c","article-title":"Adenosine A2A receptor\u2013antagonist\/dopamine D2 receptor\u2013agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers","volume":"52","author":"Soriano","year":"2009","journal-title":"J Med Chem"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2010.07.008_bb1335","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0169-328X(02)00216-4","article-title":"Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease","volume":"102","author":"Spektor","year":"2002","journal-title":"Brain Res Mol Brain Res"},{"issue":"9","key":"10.1016\/j.pharmthera.2010.07.008_bb1340","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1523\/JNEUROSCI.1658-03.2004","article-title":"Environmental enrichment rescues protein deficits in a mouse model of Huntington's Disease, indicating a possible disease mechanism","volume":"24","author":"Spires","year":"2004","journal-title":"J Neurosci"},{"issue":"6857","key":"10.1016\/j.pharmthera.2010.07.008_bb1345","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.07.008_bb1350","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.07.008_bb1355","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"40","key":"10.1016\/j.pharmthera.2010.07.008_bb1360","doi-asserted-by":"crossref","first-page":"17049","DOI":"10.1073\/pnas.0903316106","article-title":"The Tor and PKA signaling pathways independently target the Atg1\/Atg13 protein kinase complex to control autophagy","volume":"106","author":"Stephan","year":"2009","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb1365","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(93)90073-Q","article-title":"Reduced levels of 5-HT3 receptor recognition sites in the putamen of patients with Huntington's disease","volume":"242","author":"Steward","year":"1993","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb1370","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1742-4658.2009.07367.x","article-title":"ERK and cell death: ERK1\/2 in neuronal death","volume":"277","author":"Subramaniam","year":"2010","journal-title":"FEBS J"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb1375","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1074\/jbc.M310226200","article-title":"Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis","volume":"279","author":"Sugars","year":"2004","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb1380","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1083\/jcb.153.2.283","article-title":"Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression","volume":"153","author":"Suhr","year":"2001","journal-title":"J Cell Biol"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb1385","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/syn.1089","article-title":"Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers","volume":"41","author":"Suzuki","year":"2001","journal-title":"Synapse"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb1390","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1471-4159.2004.02372.x","article-title":"Distinct aggregation and cell death patterns among different types of primary neurons induced by mutant huntingtin protein","volume":"89","author":"Tagawa","year":"2004","journal-title":"J Neurochem"},{"issue":"30","key":"10.1016\/j.pharmthera.2010.07.008_bb1395","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1523\/JNEUROSCI.1396-07.2007","article-title":"Dopaminergic signaling and striatal neurodegeneration in Huntington's disease","volume":"27","author":"Tang","year":"2007","journal-title":"J Neurosci"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.07.008_bb1400","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1073\/pnas.0409402102","article-title":"Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease","volume":"102","author":"Tang","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb1405","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0896-6273(03)00366-0","article-title":"Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1, 4, 5) triphosphate receptor type 1","volume":"39","author":"Tang","year":"2003","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.07.008_bb1410","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archneur.1977.00500240044007","article-title":"Deanol acetamidobenzoate treatment in choreiform movement disorders","volume":"34","author":"Tarsy","year":"1977","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb1415","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/jnr.20138","article-title":"Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum","volume":"77","author":"Tebano","year":"2004","journal-title":"J Neurosci Res"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.07.008_bb1420","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1212\/WNL.53.7.1605","article-title":"Long-lasting improvement following (\u2212)-OSU6162 in a patient with Huntington's disease","volume":"53","author":"Tedroff","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb1425","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/(SICI)1096-9861(19980105)390:1<5::AID-CNE2>3.0.CO;2-6","article-title":"Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2\/3 in the rat basal ganglia","volume":"390","author":"Testa","year":"1998","journal-title":"J Comp Neurol"},{"issue":"Pt 4","key":"10.1016\/j.pharmthera.2010.07.008_bb1435","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/brain\/awq047","article-title":"Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease","volume":"133","author":"Thu","year":"2010","journal-title":"Brain"},{"issue":"Pt 1","key":"10.1016\/j.pharmthera.2010.07.008_bb1440","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/brain\/awl243","article-title":"Striosomes and mood dysfunction in Huntington's disease","volume":"130","author":"Tippett","year":"2007","journal-title":"Brain"},{"issue":"6779","key":"10.1016\/j.pharmthera.2010.07.008_bb1445","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/35008142","article-title":"Delaying the onset of Huntington's in mice","volume":"404","author":"van Dellen","year":"2000","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.pharmthera.2010.07.008_bb1450","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1096\/fj.03-0079fje","article-title":"Aberrant A2A receptor function in peripheral blood cells in Huntington's disease","volume":"17","author":"Varani","year":"2003","journal-title":"FASEB J"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.07.008_bb1455","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1096\/fj.00-0730fje","article-title":"Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin","volume":"15","author":"Varani","year":"2001","journal-title":"FASEB J"},{"issue":"36","key":"10.1016\/j.pharmthera.2010.07.008_bb1460","doi-asserted-by":"crossref","first-page":"14525","DOI":"10.1073\/pnas.0704482104","article-title":"Inhibitors of metabolism rescue cell death in Huntington's disease models","volume":"104","author":"Varma","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb1465","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0278-5846(90)90072-O","article-title":"Preclinical and clinical studies with cysteamine and pantethine related to the central nervous system","volume":"14","author":"Vecsei","year":"1990","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb1470","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1046\/j.1471-4159.2003.01704.x","article-title":"Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic pre-synaptic function in the striatum","volume":"85","author":"Vetter","year":"2003","journal-title":"J Neurochem"},{"issue":"16","key":"10.1016\/j.pharmthera.2010.07.008_bb1475","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/mds.21718","article-title":"Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: a double blind, randomized cross-over trial","volume":"22","author":"Vitale","year":"2007","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb1480","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/hmg\/12.6.617","article-title":"Transgenic rat model of Huntington's disease","volume":"12","author":"von Horsten","year":"2003","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb1485","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb1490","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0306-4522(89)90082-1","article-title":"Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study","volume":"32","author":"Waeber","year":"1989","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb1495","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/syn.890080405","article-title":"Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease","volume":"8","author":"Waeber","year":"1991","journal-title":"Synapse"},{"issue":"10","key":"10.1016\/j.pharmthera.2010.07.008_bb1500","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","article-title":"Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset","volume":"101","author":"Wexler","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.07.008_bb1505","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/9.4.503","article-title":"Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice","volume":"9","author":"Wheeler","year":"2000","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.07.008_bb1510","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nchembio.79","article-title":"Novel targets for Huntington's disease in an mTOR-independent autophagy pathway","volume":"4","author":"Williams","year":"2008","journal-title":"Nat Chem Biol"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2010.07.008_bb1520","first-page":"249","article-title":"Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders","volume":"73","author":"Wong","year":"1996","journal-title":"Behav Brain Res"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb1525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hum.2006.17.1","article-title":"Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications","volume":"17","author":"Wong","year":"2006","journal-title":"Hum Gene Ther"},{"issue":"9","key":"10.1016\/j.pharmthera.2010.07.008_bb1530","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1096\/fj.05-5814com","article-title":"Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration","volume":"20","author":"Woodruff","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2010.07.008_bb1535","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1750-1326-3-15","article-title":"Evaluation of Dimebon in cellular model of Huntington's disease","volume":"3","author":"Wu","year":"2008","journal-title":"Mol Neurodegener"},{"issue":"17","key":"10.1016\/j.pharmthera.2010.07.008_bb1540","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/hmg\/10.17.1829","article-title":"Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease","volume":"10","author":"Wyttenbach","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"7197","key":"10.1016\/j.pharmthera.2010.07.008_bb1545","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nature06975","article-title":"Towards a transgenic model of Huntington's disease in a non-human primate","volume":"453","author":"Yang","year":"2008","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.pharmthera.2010.07.008_bb1550","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1093\/hmg\/11.23.2905","article-title":"Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells","volume":"11","author":"Yang","year":"2002","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.07.008_bb1555","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1523\/JNEUROSCI.2309-09.2010","article-title":"Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment","volume":"30","author":"Yanpallewar","year":"2010","journal-title":"J Neurosci"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.07.008_bb1560","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.cell.2005.10.030","article-title":"In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets","volume":"123","author":"Zhai","year":"2005","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.07.008_bb1565","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Zhang","year":"2002","journal-title":"Cell Res"},{"key":"10.1016\/j.pharmthera.2010.07.008_bb1570","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.neuro.23.1.217","article-title":"Glutamine repeats and neurodegeneration","volume":"23","author":"Zoghbi","year":"2000","journal-title":"Annu Rev Neurosci"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.07.008_bb1575","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrneurol.2009.54","article-title":"Brain-derived neurotrophic factor in neurodegenerative diseases","volume":"5","author":"Zuccato","year":"2009","journal-title":"Nat Rev Neurol"},{"issue":"5529","key":"10.1016\/j.pharmthera.2010.07.008_bb1580","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.07.008_bb1585","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1750-3639.2007.00111.x","article-title":"Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease","volume":"18","author":"Zuccato","year":"2008","journal-title":"Brain Pathol"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725810001518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725810001518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T23:10:30Z","timestamp":1636067430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725810001518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":317,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0163725810001518"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2010.07.008","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}